These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
    Author: Frei R, Jones RN, Pignatari AC, Yamane N, Marco F, Hoban DJ.
    Journal: Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209.
    Abstract:
    The in vitro activity of FK-037, a new parenteral 7-aminothiazolyl-methoxyimino cephalosporin, was compared with cefepime and ceftazidime against 6094 aerobic isolates collected in six medical centers worldwide. FK-037 demonstrated potent activity against the Enterobacteriaceae family except for some Enterobacter spp., Providencia spp., and Serratia liquefaciens (MIC90s, > or = 16 micrograms/ml). Against nonenteric Gram-negative bacilli, all compounds tested showed similar, but more limited activity. The FK-037 MIC50s for Pseudomonas spp. and P. aeruginosa were 2 and 4 micrograms/ml, respectively. The least susceptible organisms were Xanthomonas maltophilia, enterococci, and Bacillus spp. (MIC50s, > 16 micrograms/ml), followed by Flavobacterium spp., other nonenterics, and oxacillin-resistant Staphylococcus aureus (MIC50s, 16 micrograms/ml). Good FK-037 activity was observed against oxacillin-susceptible staphylococci as well as against beta-hemolytic and viridans-group streptococci (MIC90 range, < or = 0.12 to 2 micrograms/ml). While FK-037 was slightly more active than cefepime against Gram-positive organisms, enteric bacilli were most susceptible to cefepime. Overall, the antibacterial spectrum of both FK-037 and cefepime was superior to ceftazidime.
    [Abstract] [Full Text] [Related] [New Search]